Preclinical development of a novel disease modifying therapy for pulmonary arterial hypertension
Ended Project Grant Awarded Last action
- Award ID
- R33HL154135
- Recipient
-
Vasculonics Inc. UEI KASJGN8XW8P8
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,033,325
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $1,632,798.98 Federal
- $400,526.00 Non-federal
- Place of performance
- Indianapolis, IN 46202, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$6 | $0 | |
| Amendment | $400,526 | $0 | |
| Amendment | $400,526 | $0 | |
| Amendment | $400,526 | $400,526 | |
| Original award | $431,227 | $0 |
Quick answers
Who received award R33HL154135?
R33HL154135 was awarded to Vasculonics Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 15, 2020.
How much is award R33HL154135 worth?
$2,033,325 has been obligated on R33HL154135: $1,632,799 in federal funding and $400,526 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award